Investigational drug · Phase 3
TR987 0.1%
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer.
Phase 3Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "TR987 0.1%"
First trial start
2025
Jan 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TR987 0.1%", any sponsor or status.
Conditions studied
As listed on its trial records.
- Venous Leg Ulcer
- Venous Ulcer
- Venous Stasis Ulcer
- Venous Stasis
- Wound Heal
- Venous Insufficiency of Leg
- Non-healing Wound
- Wound
- Wounds
Approved drugs for the same conditions: Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "TR987 0.1%" as an intervention, largest first.
- Tissue Repair Gel in Venous Leg Ulcers (US)Pivotal-lookingRecruiting
TR TherapeuticsIndustry
NCT06707090 · 312 participants (planned) · Start Jan 28, 2025 · Primary completion Dec 2027
Drug: TR987 0.1% gel + Standard of Care · For: Venous Leg Ulcer; Venous Ulcer; Venous Stasis Ulcer and 5 more
Sites: Tucson, Arizona; Castro Valley, California; Fresno, California · 33 sites in all
- Tissue Repair Gel in Venous Leg Ulcers in AU/USPivotal-lookingRecruiting
TR TherapeuticsIndustry
NCT06707103 · 312 participants (planned) · Start Apr 2025 · Primary completion Dec 2026
Drug: TR987 0.1% gel + Standard of Care · For: Venous Leg Ulcer; Venous Ulcer; Venous Stasis Ulcer and 5 more
Sites: Jacksonville, Florida; Clinton Twp, Michigan; Lake Success, New York · 12 sites in all
- Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency UlcersActive, not recruiting
SerenaGroup, Inc.Research network
NCT03154619 · 80 participants (planned) · Start Nov 2016 · Primary completion Apr 4, 2019
Drug: 0.1% TR 987; Placebo gel · For: Venous Leg Ulcer
Sites: Los Angeles, California; North Miami Beach, Florida; Pembroke Pines, Florida · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Venous Leg Ulcer
- allo-APZ2-CVUSkin-derived ABCB5-positive dermal mesenchymal stromal cellsPhase 32 trials
RHEACELL GmbH & Co. KG · Venous Leg Ulcer, Skin Ulcer Venous Stasis Chronic
- MTX-001human amniotic fluidPhase 21 trial
Merakris Therapeutics · Venous Stasis Ulcer, Venous Leg Ulcer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.